Literature DB >> 22753913

Reversing hormone resistance: have we found the golden key?

Hope S Rugo, Sara Keck.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22753913     DOI： 10.1200/JCO.2012.42.1271

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.

Authors:  Aggeliki Tserga; Ilenia Chatziandreou; Nicolaos V Michalopoulos; Efstratios Patsouris; Angelica A Saetta
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

Review 2.  Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer.

Authors:  S Chia; S Gandhi; A A Joy; S Edwards; M Gorr; S Hopkins; J Kondejewski; J P Ayoub; N Califaretti; D Rayson; S F Dent
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

Review 3.  Triple-negative breast cancer: future prospects in diagnosis and management.

Authors:  Shereef Elsamany; Sakher Abdullah
Journal:  Med Oncol       Date:  2014-01-05       Impact factor: 3.064

4.  Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.

Authors:  Longwei Qiao; Yuting Liang; Ranim R Mira; Yaojuan Lu; Junxia Gu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 5.  Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

Review 6.  Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

Authors:  Ricardo H Alvarez; Rabih I Bechara; Michael J Naughton; Javier A Adachi; James M Reuben
Journal:  Oncologist       Date:  2018-02-27

Review 7.  Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Virginia G Kaklamani
Journal:  Oncologist       Date:  2016-06-02

8.  Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.

Authors:  Ting-Yuan David Cheng; Jyoti Shankar; Gary Zirpoli; Michelle R Roberts; Chi-Chen Hong; Elisa V Bandera; Christine B Ambrosone; Song Yao
Journal:  Cancer Causes Control       Date:  2016-06-17       Impact factor: 2.506

9.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27

10.  New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Clin Risk Manag       Date:  2013-01-14       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.